Hypothesizing on how Nitrosamine Drug Substance Related Impurities (NDSRI's) are being formed?

Описание: It is a pleasure introducing Dr. Paul Harmon at our Emery Pharma Speaker Series.

Dr. Paul Harmon is a well-respected figure in the pharmaceutical and healthcare industry with a career that includes significant contributions at Merck Pharmaceutical. He served in a senior capacity at Merck, where his work focused on developmental programs and research in oxidative susceptibility testing. During his tenure, Dr. Harmon published multiple research articles and contributed to a book chapter on the topic.

In addition to his role at Merck, Dr. Harmon has also engaged in consulting through his own firm, PhaRxmon Consulting, where he offers his expertise in the pharmaceutical industry. His work spans various aspects of drug development and regulatory affairs, demonstrating a broad understanding of both scientific and commercial elements of the industry.

Dr. Harmon's academic background and professional experience have positioned him as a valuable contributor to the field, where he continues to influence through his consulting and research efforts.

Today Dr. Harmon will be speaking to us regarding Nitrosamine and how they are generated within a drug substance or drug product.

for more information please contact us at [email protected]

About Emery Pharma:
Emery Pharma is deeply committed to advancing public health and exclusively focuses on projects that enhance the well-being of both individuals and the environment. As a comprehensive contract research laboratory, Emery Pharma provides extensive support across the entire spectrum of pharmaceutical development, covering small molecule drugs, biologics, biosimilars, gene therapy, botanicals, and more.

Emery Pharma's array of premium services includes analytical and bioanalytical solutions, microbiology and cell biology services, drug and impurity characterization, and comprehensive R&D with cGMP/GLP support. The Emery Pharma team excels in customizing innovative solutions tailored to the unique requirements of each client. They seamlessly oversee the entire process, from initial drug discovery to thorough data analysis and insights generation. Their expertise allows them to tackle scientific challenges proactively, ensuring clients avoid unnecessary setbacks.

Emery Pharma's accomplished chemists and biologists harness state-of-the-art technology, encompassing cutting-edge tools such as high-resolution mass spectrometry (Orbitrap), triple quad LC-MS/MS, GC-MS, preparative HPLC, and 400 MHz multinuclear NMR.

For further details, please don't hesitate to reach out to Emery Pharma at [email protected] or explore their website at:
https://emerypharma.com/